Medable
Medable provides a platform for decentralized clinical trials, featuring tools for remote patient enrollment, electronic data capture, and AI automation.
Secondary Market Price
How Medable Measures Up
To help you manage your Medable equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Medable's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Medable Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Medable's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Medable provides a global cloud platform for managing decentralized and hybrid clinical trials. The platform offers a suite of tools that allow sponsors, contract research organizations (CROs), providers, and patients to collaborate on clinical research through features like remote patient enrollment, digital consent, electronic data capture, and telehealth visits. Founded in 2016 by Dr. Michelle Longmire and Tim Smith, the Palo Alto-based company has raised a total of $518 million in funding, including a $304 million Series D round in November 2021.
The company's current focus is on integrating artificial intelligence to automate administrative work in clinical development. Medable recently announced its TMF Agent, an AI-powered tool for organizing trial documents, and has stated a goal of using AI agents to handle 80-90% of manual administrative tasks. At the 44th J.P. Morgan Healthcare Conference, company leadership discussed how this automation can remove bottlenecks in clinical trials, reflecting a forward-looking strategy centered on increasing the speed and data transparency of clinical research.
- Blackstone Growth
- Tiger Global
- GSR Ventures
- Sapphire Ventures
- WTI
- Obvious Ventures
- PPD, Inc.
- Streamlined Ventures
- Co-Founder, Michelle Longmire
- Co-Founder, Tim Smith
- Co-Founder, James Sas
- Co-Founder, Perry Robinson
- Co-Founder, Fernando Waigandt
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Medable worth joining?
Determining if a company is the right fit involves assessing its potential and how its equity package compares to others. Platforms like Prospect can help you analyze a company's likely equity outcomes using data similar to what venture capitalists use.
What should I do with my Medable stock?
The right strategy for your stock depends on your personal financial goals, risk tolerance, and tax situation. Prospect can build a customized, multi-year plan for exercising options and selling shares to help you maximize your after-tax returns.
Can you sell Medable stock?
As a private company, Medable stock isn't traded on a public exchange, but you may be able to sell shares through secondary markets or company-approved tender offers. Prospect's tools can help you navigate these sales and identify the most tax-optimal shares to sell.
How can I find the value of my Medable stock?
The value of private stock is typically determined by a 409A valuation, but this may not reflect its market value. To get a better sense of its potential worth, you can use Prospect's predictive models, which analyze secondary market prices and other data to project future value.
What is Medable's equity worth?
The precise worth of private equity like Medable's is difficult to determine until a liquidity event like an IPO or acquisition. However, tools like Prospect can help you forecast a range of potential outcomes for your equity based on proprietary data and machine learning models.
What is Medable's stock ticker symbol?
Medable is a private company, so it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are only assigned to companies once they become publicly listed.
Can I buy or sell Medable stock?
As Medable is a private company, its stock is not available for purchase on public markets, and selling is typically limited to specific events like tender offers. Prospect can help you create a strategy for when and how to exercise options or sell shares in these situations to optimize your financial outcome.
What is the criteria to buy or invest in Medable stock?
Investing in a private company like Medable is generally restricted to employees receiving equity compensation or accredited investors participating in funding rounds. For employees, Prospect provides tools to manage and maximize the value of the equity they already hold.
